|
''Clostridium butyricum'' is a strictly anaerobic endospore-forming Gram-positive butyric acid producing bacillus subsisting by means of fermentation using an intracellularly accumulated amylopectin-like α-polyglucan (granulose) as a substrate. It is uncommonly reported as a human pathogen and is widely used as a probiotic in Asia (particularly in Japan, Korea and China).〔Seki, H., Shiohara, M., Matsumura, T., Miyagawa, N., Tanaka, M., Komiyama, A. & Kurata, S. (2003). Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI. Pediatr Int 45, 86–90〕 ''C. butyricum'' is a soil inhabitant in various parts of the world, has been cultured from the stool of healthy children and adults, and is common in soured milk and cheeses.〔Meng, X., Karasawa, T., Zou, K., Kuang, X., Wang, X., Lu, C., Wang, C., Yamakawa, K. & Nakamura, S. (1997). Characterization of a neurotoxigenic Clostridium butyricum strain isolated from the food implicated in an outbreak of food-borne type E botulism. J Clin Microbiol 35, 2160–2162.〕 ==Therapeutic Uses== The first ''C. butyricum'' MIYAIRI strain was isolated from the feces of Dr. Chikaji Miyairi in Japan in 1933, and CBM 588 is the 588th MIYAIRI strain, isolated from a soil sample in Nagano, Japan, in 1963. Preparations based on CBM 588 have a long history of safe use in human populations in Asia, especially Japan, where such products are variously classed as pharmaceutical drugs, “quasi drugs”, and OTC (Over The Counter) probiotics. The safe history of CBM 588 in human Asian populations is supported by various peer-reviewed publications and case studies dating back to 1963, including reports of CBM 588 use in severely-ill, immune-compromised and hospitalized patients, whose ages range from infants to elderly people, and include pregnant women. Its usefulness stems primarily from its ability to interfere with the growth of highly pathogenic ''Clostridium difficile'' by antagonizing its multiplication.〔Woo TD, Oka K, Takahashi M, Hojo F, Osaki T, Hanawa T, Kurata S, Yonezawa H, Kamiya S. (2011). Inhibition of the cytotoxic effect of Clostridium difficile in vitro by Clostridium butyricum MIYAIRI 588 strain. J Med Microbiol 11, 1617-25〕 It is often used in Japanese hospitals for ''C. difficile'' prophylaxis amongst in-patients and, particularly, during administration of certain powerful antibiotics (i.e.: Levofloxacin) associated with opportunistic ''C. difficile'' infection. CBM 588 was approved for clinical use in humans by the Japanese Ministry of Health and Welfare in 1970. The standard preparation as marketed by Miyarisan Pharmaceutical (Tokyo, Japan) consists of white, marked tablets each containing 0.35 x 106 colony forming units (CFU) of ''C. butyricum'' MIYAIRI 588 (as active agent). CBM 588 does not establish permanently in the gut, in common with other orally administered probiotic bacteria. CBM 588 for clinical use is produced by submerged anaerobic fermentation followed by centrifugation, drying, blending and packaging. The MIYAIRI 588 strain of ''C. butyricum'' does not carry any genes encoding any toxins and virulence factors associated with clostridium or other enteropathogens.〔http://www.food.gov.uk/multimedia/pdfs/acnfp10505clos.pdf〕 Absence of neurotoxin production has been demonstrated by polymerase chain reaction (PCR) and Southern blot hybridisation for type E botulinum toxin gene. The absence of genes encoding botulinum neurotoxin A,B,F and genes encoding non-toxic haemagglutinin (NTNH) and genes encoding ''Clostridium perfringens'' toxins (alpha, beta, epsilon and iota) has been demonstrated by PCR assay. This strain is deposited at the Fermentation Research Institute, Agency of Industrial Science and Technology, Japan under the strain name ''Clostridium butyricum'' MIYAIRI 588 strain, deposit number FERM BP-2789. Recent European Food Safety Authority opinions confirm the official strain nomenclature as ''Clostridium butyricum'' FERM BP-2789. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Clostridium butyricum」の詳細全文を読む スポンサード リンク
|